These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18563057)

  • 61. The power of pharmacoeconomics.
    Healthc Exec; 2000; 15(1):44-5. PubMed ID: 11067028
    [No Abstract]   [Full Text] [Related]  

  • 62. Considerations in the pharmacoeconomics of glaucoma.
    Hirsch JD
    Manag Care; 2002 Nov; 11(11 Suppl):32-7. PubMed ID: 15357537
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [The value of pharmaco-economics: the point of view of the drug industry].
    De Wever A
    Rev Med Liege; 1998 May; 53(5):236-41. PubMed ID: 9689874
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario?
    Preziosi P
    Nat Rev Drug Discov; 2004 Jun; 3(6):521-6. PubMed ID: 15173841
    [No Abstract]   [Full Text] [Related]  

  • 65. The relevance of international studies to informed pharmacoeconomics and health policy decisions.
    Lyles A
    Clin Ther; 2010 Jan; 32(1):106-7. PubMed ID: 20171416
    [No Abstract]   [Full Text] [Related]  

  • 66. The Canadians are killing us.
    Struble RA
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58-9. PubMed ID: 12592981
    [No Abstract]   [Full Text] [Related]  

  • 67. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Economic evaluations and diabetes.
    Pathak DS; Burke TA
    Pharm Pract Manag Q; 1998 Jan; 17(4):17-24. PubMed ID: 10174745
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Current efforts in standards development. United States.
    Power EJ
    Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327
    [No Abstract]   [Full Text] [Related]  

  • 70. Pharmaceutical economy and the economic assessment of drugs in France.
    le Pen C
    Soc Sci Med; 1997 Aug; 45(4):635-43. PubMed ID: 9226787
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost and utilisation of pharmaceuticals in Sweden.
    Ljungkvist MO; Andersson D; Gunnarsson B
    Health Policy; 1997 Sep; 41 Suppl():S55-69. PubMed ID: 10174474
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mega-mergers in the pharmaceutical industry. In whose interests?
    Po AL
    Pharmacoeconomics; 1998 Oct; 14(4):349-55. PubMed ID: 10344903
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Using pharmacoeconomics to assess the comparative value of antibacterials. A UK perspective.
    Davey P
    Pharmacoeconomics; 1996; 9 Suppl 1():26-30. PubMed ID: 10160113
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

  • 75. Drugs take the spotlight in steering clinical, economic direction for ESRD.
    Neumann ME
    Nephrol News Issues; 2004 Jun; 18(7):50-1. PubMed ID: 15232997
    [No Abstract]   [Full Text] [Related]  

  • 76. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Research on hospital drug cost control based on the perspective of pharmaceutical economy.
    Xiu Y; Jia L; Chen J; Cui W
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1057-1062. PubMed ID: 28671081
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin.
    Lopert R; Lang DL; Hill SR
    J Clin Pharm Ther; 2003 Jun; 28(3):243-9. PubMed ID: 12795784
    [TBL] [Abstract][Full Text] [Related]  

  • 79. How to improve pharmacoeconomic data generalisability between different countries.
    Li SC
    Expert Opin Pharmacother; 2007 Jul; 8(10):1409-13. PubMed ID: 17661723
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Pharmacoeconomics - Challenges for Health Professionals].
    Turčić P; Benković V; Brborović O; Valent A
    Acta Med Croatica; 2016 Apr; 70(2):117-23. PubMed ID: 28722840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.